Noxopharm (ASX: NOX) presents a Finance News Network (FNN) interview with its Chief Medical Officer, Dr Greg van Wyk, following the release of interim data for its DARRT-1 clinical trial in late-stage prostate cancer.
For more information, download the attached PDF.
Download this document
